Antibiotics that target protein synthesis

Wiley Interdisciplinary Reviews: RNA

Volumn 2, Issue 2, 2011, Pages 209-232

  Mccoy, Lisa S ^a   Xie, Yun ^a   Tor, Yitzhak ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; APRAMYCIN; BACTERIAL RNA; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN; FRAMYCETIN; GENTAMICIN; KANAMYCIN A; KANAMYCIN B; LINEZOLID; LIPOPEPTIDE; LIVIDOMYCIN; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PAROMOMYCIN; PEPTIDYLTRANSFERASE; QUINUPRISTIN; RADEZOLID; RIBONUCLEOPROTEIN; SPARSOMYCIN; STREPTOMYCIN; TEDIZOLID; TIAMULIN; TOBRAMYCIN; UNINDEXED DRUG; VIRGINIAMYCIN; VIRGINIAMYCIN S; ANTIINFECTIVE AGENT; RNA 16S; TRANSFER RNA;

DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; RIBOSOME; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BIOSYNTHESIS; RNA, RIBOSOMAL, 16S; RNA, TRANSFER;

EID: 84856170792     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.60     Document Type: Review

References (197)

1. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004, 23:113-119. doi:10.1016/j.ijantimicag.2003.11.003.
2. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Invest Drugs 2004, 13:1159-1169.
3. Garrett R, Douthwaite S, Liljas A, Matheson A, Moore P, Noller H, eds. The Ribosome: Structure, Function, Antibiotics, and Cellular Interactions. Washington, DC: ASM Press; 2000.
4. Hermann T, Tor Y. RNA as a target for small-molecule therapeutics. Expert Opin Ther Pat 2005, 15:49-62. doi:10.1517/13543776.15.1.49.
5. Wilson WD, Li K. Targeting RNA with small molecules. Curr Med Chem 2000, 7:73-98.
6. Yonath A. Antibiotics targeting ribosomes: Resistance, selectivity, synergism, and cellular regulation. Annu Rev Biochem 2005, 74:649-679. doi:10.1146/annurev.biochem.74.082803.133130.
7. Tor Y. Targeting RNA with small molecules. Chembiochem 2003, 4:998-1007. doi:10.1002/cbic.200300680.
8. Xie Y, Tam VK, Tor Y. The Interactions of Small Molecules with DNA and RNA. In: Günter M, ed. The Chemical Biology of Nucleic Acids. Chichester, UK: John Wiley & Sons, Ltd; 2010, 115-140.
9. Chow CS, Bogdan FM. A structural basis for RNA-ligand interactions. Chem Rev 1997, 97:1489-1513.
10. Leulliot N, Varani G. Current topics in RNA-protein recognition: control of specificity and biological function through induced fit and conformational capture. Biochemistry 2001, 40:7947-7956. doi:10.1021/bi010680y.
11. Hermann T. Rational ligand design for RNA: the role of static structure and conformational flexibility in target recognition. Biochimie 2002, 84:869-875. doi:10.1016/S0300-9084(02)01460-8.
12. Pitici F, Beveridge DL, Baranger AM. Molecular dynamics simulation studies of induced fit and conformational capture in U1A-RNA binding: do molecular substates code for specificity? Biopolymers 2002, 65:424-435. doi:10.1002/bip.10251.
13. Wang H, Tor Y. RNA-aminoglycoside interactions: design, synthesis, and binding of "amino-aminoglycosides" to RNA. Angew Chem Int Ed 1998, 37:109-111. doi:10.1002/(SICI)1521-3773(19980202)37:1/2109::AID-ANIE1093.0.CO;2-0.
14. Hermann T, Auffinger P, Westhof E. Molecular dynamics investigations of hammerhead ribozyme RNA. Eur Biophys J Biophys Lett 1998, 27:153-165. doi:10.1007/s002490050121.
15. Tor Y, Hermann T, Westhof E. Deciphering RNA recognition: aminoglycoside binding to the hammerhead ribozyme. Chem Biol 1998, 5:R277-R283. doi:10.1016/S1074-5521(98)90286-1.
16. Hermann T, Westhof E. Aminoglycoside binding to the hammerhead ribozyme: a general model for the interaction of cationic antibiotics with RNA. J Mol Biol 1998, 276:903-912. doi:10.1006/jmbi.1997.1590.
17. Koshland Jr. DE: Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci USA 1958, 44:98-104.
18. Williamson JR. Induced fit in RNA-protein recognition. Nat Struct Biol 2000, 7:834-837. doi:10.1038/79575.
19. Spahn CMT, Prescott CD. Throwing a spanner in the works: antibiotics and the translation apparatus. J Mol Med 1996, 74:423-439.
20. Brodersen DE, Clemons WM, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103:1143-1154. doi:10.1016/S0092-8674(00)00216-6.
21. Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 2000, 407:340-348. doi:10.1038/35030019.
22. Ogle JM, Brodersen DE, Clemons WM, Tarry MJ, Carter AP, Ramakrishnan V. Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 2001, 292:897-902. doi:10.1126/science.1060612.
23. Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V. Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell 2002, 111:721-732. doi:10.1016/S0092-8674(02)01086-3.
24. Selmer M, Dunham CM, Murphy FV, Weixlbaumer A, Petry S, Kelley AC, Weir JR, Ramakrishnan V. Structure of the 70S ribosome complexed with mRNA and tRNA. Science 2006, 313:1935-1942. doi:0.1126/science.1131127.
25. Hansen JL, Ippolito JA, Ban N, Nissen P, Moore PB, Steitz TA. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell 2002, 10:117-128. doi:10.1016/S1097-2765(02)00570-1.
26. Hansen JL, Moore PB, Steitz TA. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J Mol Biol 2003, 330:1061-1075. doi:10.1016/S0022-2836(03)00668-5.
27. Tu D, Blaha G, Moore PB, Steitz TA. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 2005, 121:257-270. doi:10.1016/j.cell.2005.02.005.
28. Ippolito JA, Kanyo ZF, Wang DP, Franceschi FJ, Moore PB, Steitz TA, Duffy EM. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 2008, 51:3353-3356. doi:10.1021/jm800379d.
29. Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 2001, 413:814-821. doi:10.1038/35101544.
30. Pioletti M, Schlunzen F, Harms J, Zarivach R, Gluhmann M, Avila H, Bashan A, Bartels H, Auerbach T, Jacobi C, et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J 2001, 20:1829-1839. doi:10.1093/emboj/20.8.1829.
31. Berisio R, Harms J, Schluenzen F, Zarivach R, Hansen HAS, Fucini P, Yonath A. Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol 2003, 185:4276-4279. doi:10.1128/jb.185.14 4276-4279.2003.
32. Berisio R, Schluenzen F, Harms J, Bashan A, Auerbach T, Baram D, Yonath A. Structural insight into the role of the ribosomal tunnel in cellular regulation. Nat Struct Biol 2003, 10:366-370. doi:10.1038/nsb915.
33. Bashan A, Agmon I, Zarivach R, Schluenzen F, Harms J, Berisio R, Bartels H, Franceschi F, Auerbach T, Hansen HAS, et al. Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression. Mol Cell 2003, 11:91-102. doi:10.1016/S1097-2765(03)00009-1.
34. Schlunzen F, Harms JM, Franceschi F, Hansen HAS, Bartels H, Zarivach R, Yonath A. Structural basis for the antibiotic activity of ketolides and azalides. Structure 2003, 11:329-338. doi:10.1016/S0969-2126(03)00022-4.
35. Harms J, Schlunzen F, Fucini P, Bartels H, Yonath A. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol 2004, 2:4. doi:10.1186/1741-7007-2-4.
36. Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 2004, 54:1287-1294. doi:10.1111/j.1365-2958.2004.04346.x.
37. Davidovich C, Bashan A, Yonath A. Structural basis for cross-resistance to ribosomal PTC antibiotics. Proc Natl Acad Sci USA 2008, 105:20665-20670. doi:10.1073/pnas.0810826105.
38. Borovinskaya MA, Pai RD, Zhang W, Schuwirth BS, Holton JM, Hirokawa G, Kaji H, Kaji A, Cate JHD. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nat Struct Mol Biol 2007, 14:727-732. doi:10.1038/nsmb1271.
39. Schroeder SJ, Blaha G, Moore PB. Negamycin binds to the wall of the nascent chain exit tunnel of the 50S ribosomal subunit. Antimicrob Agents Chemother 2007, 51:4462-4465. doi:10.1128/aac.00455-07.
40. Borovinskaya MA, Shoji S, Holton JM, Fredric K, Cate JHD. A steric block in translation caused by the antibiotic spectinomycin. ACS Chem Biol 2007, 2:545-552. doi:10.1021/ch700100n.
41. Borovinskaya MA, Shoji S, Fredrick K, Cate JHD. Structural basis for hygromycin B inhibition of protein biosynthesis. RNA 2008, 14:1590-1599. doi:10.1261/rna.1076908.
42. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 2008, 105:13339-13344. doi:10.1073/pnas.0804276105.
43. Schluenzen F, Takemoto C, Wilson DN, Kaminishi T, Harms JM, Hanawa-Suetsugu K, Szaflarski W, Kawazoe M, Shirouzo M, Nierhaus KH, et al. The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat Struct Mol Biol 2006, 13:871-878. doi:10.1038/nsmb1145.
44. Franceschi F, Duffy EM. Structure-based drug design meets the ribosome. Biochem Pharmacol 2006, 71:1016-1025. doi:10.1016/j.bcp.2005.12.026.
45. Perez A, Marchan I, Svozil D, Sponer J, Cheatham TE, Laughton CA, Orozco M. Refinenement of the AMBER force field for nucleic acids: improving the description of alpha/gamma conformers. Biophys J 2007, 92:3817-3829. doi:10.1529/biophysj.106.097782.
46. Ditzler MA, Otyepka M, Sponer J, Walter NG. Molecular dynamics and quantum mechanics of RNA: conformational and chemical change we can believe in. Acc Chem Res 2010, 43:40-47. doi:10.1021/ar900093g.
47. Zhang W, Dunkle JA, Cate JHD. Structures of the ribosome in intermediate states of ratcheting. Science 2009, 325:1014-1017. doi:10.1126/science.1175275.
48. Yoshizawa S, Fourmy D, Puglisi JD. Recognition of the codon-anticodon helix by ribosomal RNA. Science 1999, 285:1722-1725. doi:10.1126/science.285.5434.1722.
49. Kurland CG, Ehrenberg M. Growth-optimizing accuracy of gene expression. Annu Rev Biophys Biophys Chem 1987, 16:291-317.
50. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 1987, 327:389-394.
51. Botto RE, Coxon B. Nitrogen-15 nuclear magnetic resonance spectroscopy of neomycin B and related aminoglycosides. J Am Chem Soc 1983, 105:1021-1028. doi:10.1021/ja00342a062.
52. Szilagyi L, Pusztahelyi ZS, Jakab S, Kovacs I. Microscopic protonation constants in tobramycin. An NMR and pH study with the aid of partially N-acetylated derivatives. Carbohyd Res 1993, 247:99-109. doi:10.1016/0008-6215(93)84244-Z.
53. Wang H, Tor Y. Electrostatic interactions in RNA aminoglycosides binding. J Am Chem Soc 1997, 119:8734-8735. doi:10.1021/ja9715105.
54. Purohit P, Stern S. Interactions of a small RNA with antibiotic and RNA ligands of the 30S subunit. Nature 1994, 370:659-662. doi:10.1038/370659a0.
55. Recht MI, Fourmy D, Blanchard SC, Dahlquist KD, Puglisi JD. RNA sequence determinants for aminoglycoside binding to an A-site rRNA model oligonucleotide. J Mol Biol 1996, 262:421-436. doi:10.1006/jmbi.1996.0526.
56. Wong CH, Hendrix M, Priestley ES, Greenberg WA. Specificity of aminoglycoside antibiotics for the A-site of the decoding region of ribosomal RNA. Chem Biol 1998, 5:397-406. doi:10.1016/S1074-5521(98)90073-4.
57. Hermann T, Westhof E. Docking of cationic antibiotics to negatively charged pockets in RNA folds. J Med Chem 1999, 42:1250-1261. doi:10.1021/jm981108g.
58. Kaul M, Pilch DS. Thermodynamics of aminoglycoside-rRNA recognition: the binding of neomycin-class aminoglycosides to the A site of 16S rRNA. Biochemistry 2002, 41:7695-7706. doi:10.1021/bi020130f.
59. Fourmy D, Recht MI, Blanchard SC, Puglisi JD. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996, 274:1367-1371.
60. Fourmy D, Recht MI, Puglisi JD. Binding of neo mycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA. J Mol Biol 1998, 277:347-362. doi:10.1006/jmbi.1997.1552.
61. Yoshizawa S, Fourmy D, Puglisi JD. Structural origins of gentamicin antibiotic action. EMBO J 1998, 17:6437-6448. doi:10.1093/emboj/17.22.6437.
62. Vicens Q, Westhof E. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding a site. Structure 2001, 9:647-658. doi:10.1016/S0969-2126(01)00629-3.
63. Vicens Q, Westhof E. Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding a site. Chem Biol 2002, 9:747-755. doi:10.1016/S1074-5521(02)00153-9.
64. Vicens Q, Westhof E. Crystal structure of geneticin bound to a bacterial 16 S ribosomal RNA A site oligonucleotide. J Mol Biol 2003, 326:1175-1188. doi:10.1016/s0022-2836(02)01435-3.
65. Francois B, Russell RJM, Murray JB, Aboul-ela F, Masquida B, Vicens Q, Westhof E. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucl Acids Res 2005, 33:5677-5690. doi:10.1093/nar.gki862.
66. Han Q, Zhao Q, Fish S, Simonsen KB, Vourloumis D, Froelich JM, Wall D, Hermann T. Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed 2005, 44:2694-2700. doi:10.1002/anie.200500028.
67. Zhao F, Zhao Q, Blount KF, Han Q, Tor Y, Hermann T. Molecular recognition of RNA by neomycin and a restricted neomycin derivative. Angew Chem Int Ed 2005, 44:5329-5334. doi:10.1002/anie.200500903.
68. Kondo J, Francois B, Russell RJM, Murray JB, Westhof E. Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the gamma-amino-alpha-hydroxybutyryl (haba) group. Biochimie 2006, 88:1027-1031. doi:10.1016/j.biochi.2006.05.017.
69. Kondo J, Francois B, Urzhumtsev A, Westhof E. Crystal structure of the homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed 2006, 45:3310-3314. doi:10.1002/anie.200600354.
70. Hermann T, Tereshko V, Skripkin E, Patel DJ. Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis 2007, 38:193-198. doi:10.1016/j.bcmd.2006.11.006.
71. Kondo J, Hainrichson M, Nudelman I, Shallom-Shezifi D, Barbieri CM, Pilch DS, Westhof E, Baasov T. Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding a sites. Chembiochem 2007, 8:1700-1709. doi:10.1002/cbic.200700271.
72. Davies J, Gorini L, Davis BD. Misreading of RNA codewords induced by aminoglycoside antibiotics. Mol Pharmacol 1965, 1:93-106.
73. Davies J, Davis BD. Misreading of ribonucleic acid code words induced by aminoglycoside antibiotics: the effect of drug concentration. J Biol Chem 1968, 243:3312-3316.
74. Gale EF, Cundliffe E, Renolds PE, Richmond MH, Waring MJ, eds. The Molecular Basis of Antibiotic Action. New York: John Wiley & Sons; 1981.
75. Cabanas MJ, Vazquez D, Modolell J. Inhibition of ribosomal translocation by aminoglycoside antibiotics. Biochem Biophys Res Commun 1978, 83:991-997. doi:10.1016/0006-291X(78)91493-6.
76. Misumi M, Nishimura T, Komai T, Tanaka N. Interaction of kanamycin and related antibiotics with the large subunit of ribosomes and the inhibition of translocation. Biochem Biophys Res Commun 1978, 84:358-365. doi:10.1016/0006-291X(78)90178-X.
77. Fredrick K, Noller HF. Catalysis of ribosomal translocation by sparsomycin. Science 2003, 300:1159-1162. doi:10.1126/science.1084571.
78. Studer SM, Feinberg JS, Joseph S. Rapid kinetic analysis of EF-G-dependent mRNA translocation in the ribosome. J Mol Biol 2003, 327:369-381. doi:10.1016/s0022-2836(03)00146-3.
79. Peske F, Savelsbergh A, Katunin VI, Rodnina MV, Wintermeyer W. Conformational changes of the small ribosomal subunit during elongation factor G-dependent tRNA-mRNA translocation. J Mol Biol 2004, 343:1183-1194. doi:10.1016/j.jmb.2004.08.097.
80. Feldman MB, Terry DS, Altman RB, Blanchard SC. Aminoglycoside activity observed on single pre-translocation ribosome complexes. Nat Chem Biol 2010, 6:54-62. doi:10.1038/nchembio.274.
81. Yoshizawa S, Fourmy D, Eason RG, Puglisi JD. Sequence-specific recognition of the major groove of RNA by deoxystreptamine. Biochemistry 2002, 41:6263-6270. doi:10.1021/bi0121609.
82. Vicens Q, Westhof E. Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: an analysis of x-ray crystal structures. Biopolymers 2003, 70:42-57. doi:10.1002/bip.10414.
83. Ryu DH, Rando RR. Aminoglycoside binding to human and bacterial A-site rRNA decoding region constructs. Bioorgan Med Chem 2001, 9:2601-2608. doi:10.1016/S0968-0896(01)00034-7.
84. Recht MI, Douthwaite S, Puglisi JD. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J 1999, 18:3133-3138. doi:10.1006/jmbi.1998.2446.
85. Lynch SR, Puglisi JD. Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J Mol Biol 2001, 306:1037-1058. doi:10.1006/jmbi.2000.4420.
86. Kaul M, Barbieri CM, Pilch DS. Defining the basis for the specificity of aminoglycoside-rRNA recognition: A comparative study of drug binding to the A sites of Escherichia coli and human rRNA. J Mol Biol 2005, 346:119-134. doi:10.1016/j.jmb.2004.11.041.
87. Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang YS, Bottger EC, Wallace RJ. Single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Inf Dis 1998, 177:1573-1581. doi:10.1086/515328.
88. Hobbie SN, Akshay S, Kalapala SK, Bruell CM, Shcherbakov D, Bottger EC. Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci USA 2008, 105:20888-20893. doi:10.1073/pnas.0811258106.
89. Matt T, Akbergenov R, Shcherbakov D, Böttger EC. The ribosomal A-site: decoding, drug target, and disease. Israel J Chem 2010, 50:60-70. doi:10.1002/ijch.201000003.
90. Shakya T, Wright GD. Mechanisms of aminoglycoside antibiotic resistance. In: Arya DP, ed. Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery. Hoboken: John Wiley & Sons, Inc; 2007, 119-140.
91. Asensio JL, Hidalgo A, Bastida A, Torrado M, Corzana F, Chiara JL, Garcia-Junceda E, Canada J, Jimenez-Barbero J. A simple structural-based approach to prevent aminoglycoside inactivation by bacterial defense proteins. Conformational restriction provides effective protection against neomycin-B nucleotidylation by ANT4. J Am Chem Soc 2005, 127:8278-8279. doi:10.1021/ja051722z.
92. Cundliffe E. How antibiotic-producing organisms avoid suicide. Annu Rev Microbiol 1989, 43:207-233. doi:10.1146/annurev.mi.43.100189.001231.
93. Benvenis R, Davies J. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci USA 1973, 70:2276-2280.
94. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994, 264:375-382.
95. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999, 43:727-737.
96. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother 1999, 43:465-470.
97. Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003, 47:3202-3207. doi:10.1128/aac.47.10.3202-3207.2003.
98. Liou GF, Yoshizawa S, Courvalin P, Galimand M. Aminoglycoside resistance by ArmA-mediated ribosomal 16S methylation in human bacterial pathogens. J Mol Biol 2006, 359:358-364. doi:10.1016/j.jmb.2006.03.038.
99. Chittapragada M, Roberts S, Ham YW. Aminoglycosides: molecular insights on the recognition of RNA and aminoglycoside mimics. Perspectives in Medicinal Chemistry 2009, 21-37.
100. Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007, 64:1841-1852. doi:10.1007/s00018-007-7034-x.
101. Sutcliffe JA. Improving on nature: antibiotics that target the ribosome. Curr Opin Microbiol 2005, 8:534-542. doi:10.1016/j.mib.2005.08.004.
102. Umezawa H, Umezawa S, Tsuchiya T, Okazaki Y. 3′, 4′-dideoxy-kanamycin B active against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa. J Antib 1971, 24:485-487.
103. Umezawa S, Tsuchiya T, Muto R, Nishimur Y, Umezawa H. Synthesis of 3′-deoxykanamycin effective against kanamycin-resistant Escherichia coli and Pseudomonas aeruginosa. J Antib 1971, 24:274-275.
104. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T. Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 2009, 52:2243-2254. doi:10.1021/jm900028n.
105. Hainrichson M, Pokrovskaya V, Shallom-Shezifi D, Fridman M, Belakhov V, Shachar D, Yaron S, Baasov T. Branched aminoglycosides: biochemical studies and antibacterial activity of neomycin B derivatives. Bioorg Med Chem 2005, 13:5797-5807. doi:10.1016/j.bmc.2005.05.058.
106. Bera S, Zhanel GG, Schweizer F. Evaluation of amphiphilic aminoglycoside-peptide triazole conjugates as antibacterial agents. Bioorg Med Chem Lett 2010, 20:3031-3035. doi:10.1016/j.bmcl.2010.03.116.
107. Kawaguchi H, Naito T, Nakagawa S, Fujisawa K. BB-K 8, a new semisynthetic aminoglycoside antibiotic. J Antib 1972, 25:695-708.
108. Blount KF, Zhao F, Hermann T, Tor Y. Conformational constraint as a means for understanding RNA-aminoglycoside specificity. J Am Chem Soc 2005, 127:9818-9829. doi:10.1021/ja050918w.
109. Bastida A, Hidalgo A, Chiara JL, Torrado M, Corzana F, Perez-Canadillas JM, Groves P, Garcia-Junceda E, Gonzalez C, Jimenez-Barbero J, et al. Exploring the use of conformationally locked aminoglycosides as a new strategy to overcome bacterial resistance. J Am Chem Soc 2006, 128:100-116. doi:10.1021/ja0543144.
110. Greenberg WA, Priestley ES, Sears PS, Alper PB, Rosenbohm C, Hendrix M, Hung SC, Wong CH. Design and synthesis of new aminoglycoside antibiotics containing neamine as an optimal core structure: correlation of antibiotic activity with in vitro inhibition of translation. J Am Chem Soc 1999, 121:6527-6541. doi:10.1021/ja9910356.
111. Hanessian S, Tremblay M, Kornienko A, Moitessier N. Design, modeling and synthesis of functionalized paromamine analogs. Tetrahedron 2001, 57:3255-3265. doi:10.1016/S0040-4020(01)00194-6.
112. Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu MZ, Vakulenko SB, Chow CS, Mobashery S. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc 2002, 124:3229-3237. doi:10.1021/ja011695m.
113. Ding YL, Hofstadler SA, Swayze EE, Risen L, Griffey RH. Design and synthesis of paromomycin-related heterocycle-substituted aminoglycoside mimetics based on a mass spectrometry RNA-binding assay. Angew Chem Int Ed 2003, 42:3409-3412. doi:10.1002/anie.200351354.
114. Ding YL, Hofstadler SA, Swayze EE, Griffey RH. Efficient synthesis of heterocyclic 2-deoxysteptamine derivatives as RNA binding ligands. Chem Lett 2003, 32:908-909. doi:10.1246/cl.2003.908.
115. Wang XJ, Migawa MT, Sannes-Lowery KA, Swayze EE. The synthesis and 16S A-site rRNA recognition of carbohydrate-free aminoglycosides. Bioorg Med Chem Lett 2005, 15:4919-4922. doi:10.1016/j.bmcl.2005.08.027.
116. Barluenga S, Simonsen KB, Littlefield ES, Ayida BK, Vourloumis D, Winters GC, Takahashi M, Shandrick S, Zhao Q, Han Q, et al. Rational design of azepane-glycoside antibiotics targeting the bacterial ribosome. Bioorg Med Chem Lett 2004, 14:713-718. doi:10.1016/j.bmcl.2003.11.028.
117. Zhou YF, Sun ZX, Froelich JM, Hermann T, Wall D. Structure-activity relationships of novel antibacterial translation inhibitors: 3, 5-Diamino-piperidinyl triazines. Bioorg Med Chem Lett 2006, 16:5451-5456. doi:10.1016/j.bmcl.2006.07.052.
118. Barbieri CM, Kaul M, Bozza-Hingos M, Zhao F, Tor Y, Hermann T, Pilch DS. Defining the molecular forces that determine the impact of neomycin on bacterial protein synthesis: importance of the 2′-amino functionality. Antimicrob Agents Chemother 2007, 51:1760-1769. doi:10.1128/aac.
119. Russell RJM, Murray JB, Lentzen G, Haddad J, Mobashery S. The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chem Soc 2003, 125:3410-3411. doi:10.1021/ja029736h.
120. Fong DH, Berghuis AM. Substrate promiscuity of an aminoglycoside antibiotic resistance enzyme via target mimicry. EMBO J 2002, 21:2323-2331. doi:10.1093/emboj/21.10.2323.
121. Disney MD, Seeberger PH. Aminoglycoside microarrays to explore interactions of antibiotics with RNAs and proteins. Chem Eur J 2004, 10:3308-3314. doi:10.1002/chem.200306017.
122. Foloppe N, Chen IJ, Davis B, Hold A, Morley D, Howes R. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. Bioorg Med Chem 2004, 12:935-947. doi:10.1016/j.bmc.2003.12.023.
123. Griffey RH, Hofstadler SA, Sannes-Lowery KA, Ecker DJ, Crooke ST. Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc Natl Acad Sci USA 1999, 96:10129-10133.
124. Sannes-Lowery KA, Griffey RH, Hofstadler SA. Measuring dissociation constants of RNA and aminoglycoside antibiotics by electrospray ionization mass spectrometry. Anal Biochem 2000, 280:264-271. doi:10.1006/abio.2000.4550.
125. Swayze EE, Jefferson EA, Sannes-Lowery KA, Blyn LB, Risen LM, Arakawa S, Osgood SA, Hofstadler SA, Griffey RH. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J Med Chem 2002, 45:3816-3819. doi:10.1021/jm0255466.
126. Yu LP, Oost TK, Schkeryantz JM, Yang JG, Janowick D, Fesik SW. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J Am Chem Soc 2003, 125:4444-4450. doi:10.1021/ja021354o.
127. Johnson EC, Feher VA, Peng JW, Moore JM, Williamson JR. Application of NMR SHAPES screening to an RNA target. J Am Chem Soc 2003, 125:15724-15725. doi:10.1021/ja037499s.
128. Shandrick S, Zhao Q, Han Q, Ayida BK, Takahashi M, Winters GC, Simonsen KB, Vourloumis D, Hermann T. Monitoring molecular recognition of the ribosomal decoding site. Angew Chem Int Ed 2004, 43:3177-3182. doi:10.1002/anie.200454217.
129. Kaul M, Barbieri CM, Pilch DS. Fluorescence-based approach for detecting and characterizing anti biotic-induced conformational changes in ribosomal RNA: comparing aminoglycoside binding to prokaryotic and eukaryotic ribosomal RNA sequences. J Am Chem Soc 2004, 126:3447-3453. doi:10.1021/ja030568i.
130. Xie Y, Dix AV, Tor Y. FRET enabled real time detection of RNA-small molecule binding. J Am Chem Soc 2009, 131:17605-17614. doi:10.1021/ja905767g.
131. Xie Y, Dix AV, Tor Y. Antibiotic selectivity for prokaryotic vs. eukaryotic decoding sites. Chem Commun 2010, 46:5542-5544. doi:10.1039/c0cc00423e.
132. Rodnina MV, Beringer M, Wintermeyer W. How ribosomes make peptide bonds. Trends Biochem Sci 2007, 32:20-26. doi:10.1016/j.tibs.2006.11.007.
133. Schmeing TM, Huang KS, Kitchen DE, Strobel SA, Steitz TA. Structural insights into the roles of water and the 2′ hydroxyl of the P site tRNA in the peptidyl transferase reaction. Mol Cell 2005, 20:437-448. doi:10.1016/j.molcel.2005.09.006.
134. Schmeing TM, Huang KS, Strobel SA, Steitz TA. An induced-fit mechanism to promote peptide bond formation and exclude hydrolysis of peptidyl-tRNA. Nature 2005, 438:520-524. doi:10.1038/nature04152.
135. Moazed D, Noller HF. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie 1987, 69:879-884. doi:10.1016/0300-9084(87)90215-X.
136. Mankin AS, Garrett RA. Chloramphenicol resistance mutations in the single 23S rRNA gene of the archaeon Halobacterium halobium. J Bacteriol 1991, 173:3559-3563.
137. Douthwaite S. Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA. Nucl Acids Res 1992, 20:4717-4720.
138. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003, 330:1005-1014. doi:10.1016/S0022-2836(03)00662-4.
139. Hogenauer G. The mode of action of pleuromutilin derivatives. Location and properties of the pleuromutilin binding site on Escherichia coli ribosomes. Eur J Biochem 1975, 52:93-98. doi:10.1111/j.1432-1033.1975.tb03976.x.
140. Egger H, Reinshagen H. New pleutromutilin derivatives with enhanced antimicrobial activity II. Structure-activity correlations. J Antib 1976, 29:923-927.
141. Poulsen SM, Karlsson M, Johansson LB, Vester B. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol Microb 2001, 41:1091-1099. doi:10.1111/j.1365-2958.2001.02595.x.
142. Hogenauer G, Egger H, Ruf C, Stumper B. Affinity labeling of Escherichia coli ribosomes with a covalently binding derivative of the antibiotic pleuromutilin. Biochemistry 1981, 20:546-552. doi:10.1021/bi00506a016.
143. Lazaro E, Vandenbroek L, Felix AS, Ottenheijm HCJ, Ballesta JPG. Biochemical and kinetic characteristics of the interaction of the antitumor antibiotic sparsomycin with prokaryotic and eukaryotic ribosomes. Biochemistry 1991, 30:9642-9648. doi:10.1021/bi00104a011.
144. Porse BT, Kirillov SV, Awayez MJ, Ottenheijm HCJ, Garrett RA. Direct crosslinking of the antitumor antibiotic sparsomycin, and its derivatives, to A2602 in the peptidyl transferase center of 23S-like rRNA within ribosome-tRNA complexes. Proc Natl Acad Sci USA 1999, 96:9003-9008.
145. Monro RE, Celma ML, Vazquez D. Action of sparsomycin on ribosome-catalysed peptidyl transfer. Nature 1969, 222:356-358. doi:10.1038/222356a0.
146. Cocito C. Antibiotics of the virginiamycin family, inhibitors which contain synergistic components. Microbiol Rev 1979, 43:145-198.
147. Cocito C, DiGiambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997, 39:7-13.
148. Mukhtar TA, Wright GD. Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem Rev 2005, 105:529-542. doi:10.1021/cr030110z.
149. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
150. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 36:159-168.
151. Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H, Wintermeyer W. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 1999, 5:939-946.
152. Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003, 278:21972-21979. doi:10.1074/jbc.M302109200.
153. Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR, Thomasco LM, Gadwood RC, Shinabarger D, Xiong LQ, Mankin AS. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007, 26:393-402. doi:10.1016/j.molcel.2007.04.005.
154. Kloss P, Xiong LQ, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999, 294:93-101.
155. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208. doi:10.1016/S0140-6736(01)05410-1.
156. Zhou JC, Bhattacharjee A, Chen SL, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou RL, et al. Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics. Bioorg Med Chem Lett 2008, 18:6175-6178. doi:10.1016/j.bmcl.2008.10.011.
157. Zhou JC, Bhattacharjee A, Chen SL, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou RL, et al. Design at the atomic level: generation of novel hybrid biaryloxazolidinones as promising new antibiotics. Bioorg Med Chem Lett 2008, 18:6179-6183. doi:10.1016/j.bmcl.2008.10.014.
158. Rib-X Pharmaceuticals: Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumoniae. Press Release, 2009, August 4.
159. Trius Therapeutics Inc.: Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections. Press Release, 2009, June 8.
160. Nissen P, Hansen J, Ban N, Moore PB, Steitz TA. The structural basis of ribosome activity in peptide bond synthesis. Science 2000, 289:920-930. doi:10.1126/science.289.5481.920.
161. Tenson T, Ehrenberg M. Regulatory nascent peptides in the ribosomal tunnel. Cell 2002, 108:591-594. doi:10.1016/S0092-8674(02)00669-4.
162. Gong F, Yanofsky C. Instruction of translating ribosome by nascent peptide. Science 2002, 297:1864-1867. doi:10.1126/science.1073997.
163. Nakatogawa H, Ito K. The ribosomal exit tunnel functions as a discriminating gate. Cell 2002, 108:629-636. doi:10.1016/S0092-8674(02)00649-9.
164. Otaka T, Kaji A. Release of (oligo)peptidyl-tRNA from ribosomes by erythromycin A. Proc Natl Acad Sci USA 1975, 72:2649-2652.
165. Mao JCH, Robishaw EE. Effects of macrolides on peptide-bond formation and translocation. Biochemistry 1971, 10:2054-2061. doi:10.1021/bi00787a014.
166. Poulsen SM, Kofoed C, Vester B. Inhibition of the ribosomal peptidyl transferase reaction by the mycarose moiety of the antibiotics carbomycin, spiramycin and tylosin. J Mol Biol 2000, 304:471-481. doi:10.1006/jmbi.2000.4229.
167. Whaley HA, Patterson EL, Dornbush AC, Backus EJ, Bohonos N. Isolation and characterization of relomycin a new antibiotic. Antimicrob Agents Chemother 1964, 45-48.
168. Omura S, Tishler M, Nakagawa A, Hironaka Y, Hata T. Relation of structures and microbiological activities of the 16-membered macrolides. J Med Chem 1972, 15:1011-1015. doi:10.1021/jm00280a003.
169. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Inf 2000, 6:661-669. doi:10.1111/j.1469-0691.2000.00185.x.
170. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999, 31:623-631. doi:10.1046/j.1365-2958.1999.01202.
171. Liu MF, Douthwaite S. Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother 2002, 46:1629-1633. doi:10.1128/aac.46.6.1629-1633.2002.
172. Depardieu F, Courvalin P. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001, 45:319-323. doi:10.1128/AAC.45.1.319-323.2001.
173. Clancy J, Petitpas J, DibHajj F, Yuan W, Cronan M, Kamath AV, Bergeron J, Retsema JA. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol 1996, 22:867-879. doi:10.1046/j.1365-2958.1996.01521.x.
174. Chesneau O, Tsvetkova K, Courvalin P. Resistance phenotypes conferred by macrolide phosphotransferases. Fems Microbiol Lett 2007, 269:317-322. doi:10.1111/j.1574-6968.2007.00643.x.
175. Wittmann HG, Stoffler G, Apirion D, Rosen L, Tanaka K, Tamaki M, Takata R, Dekio S, Otaka E, Osawa S. Biochemical and genetic studies on two different types of erythromycin resistant mutants of Escherichia coli with altered ribosomal proteins. Mol Gen Genet 1973, 127:175-189. doi:10.1007/BF00333665.
176. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002, 46:125-131. doi:10.1128/AAC.46.1.125-131.2002.
177. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995, 39:577-585.
178. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001, 45:1-12. doi:10.1128/AAC.45.1.1-12.2001.
179. Advanced Life Sciences Inc.: Cethromycin achieves all endpoints in second pivotal phase III trial for treatment of pneumonia. Press Release, 2007, November 15.
180. Enanta Pharmaceuticals: Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia. Press Release, 2006, January 19.
181. Olson MW, Ruzin A, Feyfant E, Rush TS, O'Connell J, Bradford PA. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006, 50:2156-2166. doi:10.1128/aac.01499-05.
182. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65:232-260. doi:10.1128/MMBR.65.2.232-260.2001.
183. Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, Strick CA, Su WG, Sutcliffe J, Wondrack L. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996, 40:2226-2228.
184. Shoji S, Walker SE, Fredrick K. Ribosomal translocation: one step closer to the molecular mechanism. ACS Chem Biol 2009, 4:93-107. doi:10.1021/cb8002946.
185. Brandi L, Fabbretti A, Pon CL, Dahlberg AE, Gualerzi CO. Initiation of protein synthesis: a target for antimicrobials. Expert Opin Ther Targ 2008, 12:519-534. doi:10.1517/14728220802062338.
186. Dinos G, Wilson DN, Teraoka Y, Szaflarski W, Fucini P, Kalpaxis D, Nierhaus KH. Dissecting the ribosomal inhibition mechanisms of edeine and pactamycin: the universally conserved residues G693 and C795 regulate P-site RNA binding. Mol Cell 2004, 13:113-124. doi:10.1016/S1097-2765(04)00002-4.
187. Arakawa M, Shiozuka M, Nakayama Y, Hara T, Hamada M, Kondo S, Ikeda D, Takahashi Y, Sawa R, Nonomura Y, et al. Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 2003, 134:751-758. doi:10.1093/jb/mvg203.
188. Harms JM, Wilson DN, Schluenzen F, Connell SR, Stachelhaus T, Zaborowska Z, Spahn CMT, Fucini P. Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell 2008, 30:26-38. doi:10.1016/j.molcel.2008.01.009.
189. Yassin A, Mankin AS. Potential new antibiotic sites in the ribosome revealed by deleterious mutations in RNA of the large ribosomal subunit. J Biol Chem 2007, 282:24329-24342. doi:10.1074/jbc.M703106200.
190. Michael K, Tor Y. Designing novel RNA binders. Chem Eur J 1998, 4:2091-2098. doi:10.1002/(SICI)1521-3765(19981102)4:112091::AID-CHEM20913.0.CO;2-3.
191. Tor Y. RNA and the small molecule world. Angew Chem Int Ed 1999, 38:1579-1582.
192. Hermann T, Westhof E. RNA as a drug target: chemical, modelling, and evolutionary tools. Curr Opin Biotechnol 1998, 9:66-73. doi:10.1016/S0958-1669(98)80086-4.
193. Miller JR, Waldrop GL. Discovery of novel antibacterials. Expert Opin Drug Disc 2010, 5:145-154. doi:10.1517/17460440903493449.
194. Galloway W, Bender A, Welch M, Spring DR, The discovery of antibacterial agents using diversity-oriented synthesis. Chem Commun 2009:2446-2462.
195. Leeds JA, Schmitt EK, Krastel P. Recent developments in antibacterial drug discovery: microbe-derived natural products-from collection to the clinic. Expert Opin Invest Drugs 2006, 15:211-226. doi:10.1517/13543784.15.3.211.
196. Richards JJ, Melander C. Controlling Bacterial Biofilms. Chembiochem 2009, 10:2287-2294. doi:10.1002/cbic.200900317.
197. Sykes RB. The magic bullet in the new millennium-Cause for optimism. J Inf Chemother 2002, 8:121-124. doi:10.1007/s101560200021.